- Home
- DAWN vs AFYA Comparison
DAWN vs AFYA Comparison
Compare DAWN & AFYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- AFYA
- Stock Information
- Founded
- DAWN 2018
- AFYA 1999
- Country
- DAWN United States
- AFYA Brazil
- Employees
- DAWN N/A
- AFYA N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- AFYA Other Consumer Services
- Sector
- DAWN Health Care
- AFYA Real Estate
- Exchange
- DAWN Nasdaq
- AFYA Nasdaq
- Market Cap
- DAWN 1.6B
- AFYA 1.6B
- IPO Year
- DAWN 2021
- AFYA 2019
- Fundamental
- Price
- DAWN $13.34
- AFYA $16.26
- Analyst Decision
- DAWN Strong Buy
- AFYA Hold
- Analyst Count
- DAWN 7
- AFYA 4
- Target Price
- DAWN $36.17
- AFYA $21.13
- AVG Volume (30 Days)
- DAWN 1.3M
- AFYA 120.1K
- Earning Date
- DAWN 10-30-2024
- AFYA 11-13-2024
- Dividend Yield
- DAWN N/A
- AFYA N/A
- EPS Growth
- DAWN N/A
- AFYA 61.94
- EPS
- DAWN N/A
- AFYA 1.17
- Revenue
- DAWN $101,953,000.00
- AFYA $584,951,886.00
- Revenue This Year
- DAWN N/A
- AFYA $19.06
- Revenue Next Year
- DAWN $44.21
- AFYA $11.30
- P/E Ratio
- DAWN N/A
- AFYA $13.98
- Revenue Growth
- DAWN N/A
- AFYA 16.67
- 52 Week Low
- DAWN $11.30
- AFYA $15.52
- 52 Week High
- DAWN $18.07
- AFYA $22.48
- Technical
- Relative Strength Index (RSI)
- DAWN 38.64
- AFYA 41.44
- Support Level
- DAWN $12.86
- AFYA $15.52
- Resistance Level
- DAWN $13.71
- AFYA $16.60
- Average True Range (ATR)
- DAWN 0.77
- AFYA 0.54
- MACD
- DAWN -0.25
- AFYA -0.15
- Stochastic Oscillator
- DAWN 12.24
- AFYA 25.52
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About AFYA Afya Limited
Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medicine, other health sciences, and other undergraduate programs, Continuing Education provides specialization programs and graduate courses in medicine; and Digital Services provides content and technology for medical education, clinical decisions software, practice management tools (that encompass electronic medical records, telemedicine, and digital prescription, and provides access, demand and efficiency for the healthcare players.